<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011816</url>
  </required_header>
  <id_info>
    <org_study_id>SR-BX01-2007</org_study_id>
    <nct_id>NCT01011816</nct_id>
  </id_info>
  <brief_title>Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System</brief_title>
  <official_title>A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spinal Restoration, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spinal Restoration, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to establish the safety and efficacy of the Biostat
      System when used for treatment of chronic low back (lumbar) pain due to symptomatic internal
      disc disruptions (IDD) by comparing safety and efficacy outcome measures between one group
      receiving BIOSTAT BIOLOGX® Fibrin Sealant through the Biostat® Delivery Device and another
      group receiving a preservative-free normal saline control delivered with the Biostat Delivery
      Device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Biostat System is a combination product combining a resorbable biologic product with a
      delivery device system used to prepare and insert the biologic material into a lumbar
      intervertebral disc.

      Symptomatic IDD is defined as a painful disruption of the internal architecture of a lumbar
      intervertebral disc, which appears as fissures, cracks or tears within the internal
      structures of the disc. Pain arising from a lumbar disc may not only be perceived as pain
      located in the low back (axial pain) but also as somatic referred pain involving the
      posterior hips, buttocks, lateral hips, groin, or posterior thighs.

      The diagnosis of symptomatic IDD cannot currently be made on the basis of imaging studies,
      physical examination, or symptoms alone, and is best established with meticulously conducted
      disc provocation studies (provocation discography) that include pressure manometry and
      identification of an adjacent normal disc.

      This treatment and study are not designed for patients exhibiting other potential sources of
      chronic low back pain such as more advanced degenerative disc disease with significant loss
      of disc height (&gt;33%), spinal stenosis, or spondylolisthesis (see Eligibility Criteria).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped prior to last subject's last extended follow-up visit (78 weeks) due to lack of
    efficacy at the primary study endpoint (26 weeks)
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Composite Success</measure>
    <time_frame>26 weeks</time_frame>
    <description>Subject success based on a composite of minimum 30% decrease in low back pain, 30% improvement in function, maintenance of neurological status, no secondary interventions, and no serious adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Low Back Pain</measure>
    <time_frame>26-weeks</time_frame>
    <description>Percent of subjects achieving a minimum 30% decrease in pain from baseline.
The visual analog scale is a horizontal 100 mm line anchored on the left with the words &quot;No Pain&quot; and on the right with the words &quot;Worst Possible Pain&quot;. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the subject to indicate the subject's level of low back pain experienced over the last week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Roland-Morris Disability Questionnaire Score</measure>
    <time_frame>26-weeks</time_frame>
    <description>Percent of subjects achieving a minimum 30% decrease in Roland-Morris Disability Questionnaire score
The Roland-Morris Disability Questionnaire is a widely studied and frequently used instrument for the assessment of function and disability related to low back pain. The questionnaire consists of 24 statements related to how a subject's back condition affects various activities of daily living. Subjects marked whether the statement either applied to them or did not apply at the time they responded to the statements. The score is the total number of questions with which the subject agreed. A higher score indicates less function and greater disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Back Pain</condition>
  <condition>Chronic Low Back Pain</condition>
  <condition>Internal Disc Disruption</condition>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>BIOSTAT BIOLOGX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BIOSTAT BIOLOGX</intervention_name>
    <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
    <arm_group_label>BIOSTAT BIOLOGX</arm_group_label>
    <other_name>Fibrin Sealant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>One injection of up to 4 mL of saline using the Biostat Delivery Device</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>0.9% w/v Sodium Chloride Injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older and skeletally mature.

          -  Voluntarily signs the subject informed consent form and agrees to the release of
             medical information for purposes of this study (HIPAA authorization).

          -  Physically and mentally able to comply with the protocol, including ability to read
             and complete required forms, and willing and able to adhere to the follow-up
             requirements of the protocol.

          -  Chronic low back pain for at least 6 months.

          -  Pretreatment baseline low back pain of at least 40 mm on a 100 mm visual analog scale.

          -  Pretreatment baseline Roland-Morris Disability Questionnaire score of at least 9 on
             the 24-point questionnaire.

          -  Leg pain, if present, is of nonradicular origin, i.e., not due to stimulation of nerve
             roots or dorsal root ganglion of a spinal nerve by compressive forces.

          -  Leg pain, if present, does not extend below the knee and is no greater than 50% of low
             back pain as measured on a visual analog scale. If bilateral leg pain, the worst leg
             pain is no greater than 50% of low back pain.

          -  Low back pain unresponsive to at least 3 months of nonoperative care, which may
             include bed rest, antiinflammatory and analgesic medications, chiropractic
             manipulations, acupuncture, massage, physical therapy or home-directed lumbar exercise
             program.

          -  Diagnostic medial branch block or facet joint injection between 18 months and 2 weeks
             prior to the study procedure indicates no facet joint involvement.

          -  Diagnosis of symptomatic lumbar (L1-L2 - L5-S1) internal disc disruption (IDD), which
             requires confirmation of discogenic pain at one or two contiguous levels through
             positive provocation discography performed between 18 months and 2 weeks prior to the
             study procedure using pressure manometry and identification of an adjacent nonpainful
             disc. The disc provocation studies must precisely demonstrate concordant pain (&lt;50 psi
             above opening pressure) and must demonstrate a fissure(s) in the outer one-third of
             the posterior or lateral anulus.

        Exclusion Criteria:

          -  Cauda equina syndrome.

          -  Active malignancy or tumor as source of symptoms.

          -  Current infection or prior history of spinal infection (e.g., discitis, septic
             arthritis, epidural abscess) or an active systemic infection.

          -  Previous lumbar spine surgery.

          -  Evidence of prior lumbar vertebral body fracture.

          -  Disc bulge/protrusion or focal herniation at the symptomatic level(s) &gt; 4 mm.

          -  Presence of disc extrusion or sequestration.

          -  Leg pain is greater than 50% of low back pain as measured on a visual analog scale.

          -  Leg pain that extends below the knee.

          -  Lumbar intervertebral foramen stenosis at the affected level(s) resulting in
             significant spinal nerve root compression (effacement of the majority of periganglion
             fat and loss of CSF signal around the nerve rootlets).

          -  Symptomatic central vertebral canal stenosis or absolute sagittal vertebral canal
             diameter &lt; 9mm.

          -  Loss of disc space height at the symptomatic level(s) greater than one-third of an
             adjacent normal disc (or of the expected height in the case of an L5-S1 disc).

          -  Spondylolisthesis (&gt; Grade 1) with or without spondylolysis at the symptomatic
             level(s).

          -  Lumbar spondylitis or other undifferentiated spondyloarthropathy.

          -  Dynamic instability at the symptomatic level(s) on lumbar flexion-extension
             radiographs indicated by &gt;4.5 mm of translation or angular motion &gt;15° at L1-L2,
             L2-L3, or L3-L4; &gt;20° at L4-L5; or &gt;25° at L5-S1.

          -  Diagnostic medial branch block or facet joint injection indicate facet joint
             involvement.

          -  Diagnostic sacroiliac injection indicates sacroiliac joint involvement for those
             patients with pain in the sacral region.

          -  Sustained relief (&gt;3 months) of low back pain obtained with epidural injection of
             corticosteroids.

          -  Symptomatic involvement of more than two lumbar disc levels determined from
             discography.

          -  Neurological examination shows findings of radiculopathy or a significant underlying
             neurological condition (motor strength &lt;4; sensory assessment abnormal; or reflexes
             absent or hyperactive with clonus).

          -  Prior thermal intradiscal procedure (e.g., intradiscal electrothermal therapy,
             intradiscal radiofrequency thermocoagulation).

          -  Any lumbar intradiscal injection procedure other than discography (e.g., injection of
             corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate).

          -  Significant systemic disease, including unstable angina, autoimmune disease,
             rheumatoid arthritis, and muscular dystrophy.

          -  Congenital or acquired coagulopathy or thrombocytopenia; or currently taking
             anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications;
             or undergoing radiation therapy.

          -  History of unexplained, easy, or persistent bruising or bleeding, bleeding from the
             gums, or bleeding problems experienced in previous surgical procedures.

          -  Aspirin or aspirin-containing medication taken ≤ 7 days prior to the procedure.

          -  Known or suspected hypersensitivity or allergy to drugs or components of the fibrin
             sealant (fibrinogen, thrombin, aprotinin, CaCl2) used in the procedure.

          -  History of, or current psychiatric or psychological condition, or substance or alcohol
             abuse that would potentially interfere with the subject's participation in the study.

          -  Ongoing or previous participation in another drug or device clinical study within the
             previous 2 months.

          -  Subject known to be pregnant or nursing at time of enrollment or with plans to become
             pregnant within the planned length of follow-up.

          -  Body habitus precludes adequate fluoroscopic visualization for the procedure or the
             procedure is physically impossible using the device.

          -  Concomitant conditions requiring daily oral steroid use for more than 30 days in the
             preceding 90 days.

          -  Pending litigation against a health care professional, except where required by the
             insurer as a condition of coverage, personal injury compensation or litigation claims.

          -  Prisoner or active military personnel who would not be available for follow-up.

          -  Presence of ferromagnetic implants that would disallow MRI of the symptomatic disc(s).

          -  Active or pending workers' compensation claims.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin J Pauza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spine Specialists PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Control Associates of San Diego</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Napa Pain Institute</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Spine Diagnostics</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Spine Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pain Institute, Inc</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32953</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Spine Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Advanced Pain Specialists Applied Research Center</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewSouth NeuroSpine Pain Center</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Spine Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoNeuro, Inc.</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Pain Management</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic &amp; Spine Specialists</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Specialists PA</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Spine Research Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pain Management</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellingham Spine Pain Specialists PS</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yin W, Pauza K, Olan W, Doerzbacher JF. Intradiscal injection of fibrin sealant for the treatment of symptomatic internal disc disruption: results of a prospective multicenter IDE pilot study with 6-month follow-up [ISIS Abstract]. Pain Medicine 10(5):955, 2009.</citation>
  </reference>
  <reference>
    <citation>Buser Z, Keulling F, Jane L, Liebenberg E, Tang J, Thorne K, Coughlin D, Lotz J. Fibrin injection stimulates early disc healing in the porcine model [NASS Abstract 199]. Spine Journal 9:105S, 2009.</citation>
  </reference>
  <reference>
    <citation>Buser Z, Kuelling F, Liu J, Liebenberg E, Thorne KJ, Coughlin D, Lotz JC. Biological and biomechanical effects of fibrin injection into porcine intervertebral discs. Spine (Phila Pa 1976). 2011 Aug 15;36(18):E1201-9. doi: 10.1097/BRS.0b013e31820566b2.</citation>
    <PMID>21325992</PMID>
  </reference>
  <reference>
    <citation>Pauza K, Yin W, Olan W, Doerzbacher JF. BIOSTAT BIOLOGX(R) intradiscal fibrin sealant used for treatment of chronic low back pain caused by lumbar disc disruption: results of a 12 month, prospective multicenter pilot study. Spine Arthroplasty Society Meeting, April 27-30, 2010; New Orleans, LA. Abstract 248.</citation>
  </reference>
  <reference>
    <citation>Yin W, Pauza K, Olan W, Doerzbacher JF. Long-term outcomes from a prospective, multicenter investigational device exemption (IDE) pilot study of intradiscal fibrin sealant for the treatment of discogenic pain [ISIS Abstract]. Pain Medicine 12:1446-1447, 2011</citation>
  </reference>
  <reference>
    <citation>Buser Z, Liu J, Thorne KJ, Coughlin D, Lotz JC. Inflammatory response of intervertebral disc cells is reduced by fibrin sealant scaffold in vitro. J Tissue Eng Regen Med. 2014 Jan;8(1):77-84. doi: 10.1002/term.1503. Epub 2012 May 18.</citation>
    <PMID>22610998</PMID>
  </reference>
  <reference>
    <citation>Yin W, Pauza K, Olan WJ, Doerzbacher JF, Thorne KJ. Intradiscal injection of fibrin sealant for the treatment of symptomatic lumbar internal disc disruption: results of a prospective multicenter pilot study with 24-month follow-up. Pain Med. 2014 Jan;15(1):16-31. doi: 10.1111/pme.12249. Epub 2013 Oct 23.</citation>
    <PMID>24152079</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>April 2, 2014</results_first_submitted>
  <results_first_submitted_qc>April 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intervertebral disk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIOSTAT BIOLOGX</title>
          <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>26-Week Primary Endpoint</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>78-Week Extended Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIOSTAT BIOLOGX</title>
          <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" spread="10.7"/>
                    <measurement group_id="B2" value="41.9" spread="11.4"/>
                    <measurement group_id="B3" value="40.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥18-≤29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30-≤39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥40-≤49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50-≤59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="6.1"/>
                    <measurement group_id="B2" value="27.5" spread="5.6"/>
                    <measurement group_id="B3" value="27.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Currently Employed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Back Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History Low Back Pain</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0.5 - 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - &lt;5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - &lt;10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - &lt;20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History Right Leg Pain</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - &lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - &lt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - &lt;4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History Left Leg Pain</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - &lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - &lt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - &lt;4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=4years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Opioid Medication for Back Pain</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar Level Treated</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>L3/L4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L4/L5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L5/S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reason for Stopping Injection</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Subject Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Pressure Reached</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Available Volume Delivered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other [investigator discretion; saline backflow]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Injection Pressure</title>
          <description>n=163 BIOSTAT BIOLOGX n=55 Saline</description>
          <units>psi</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.0" spread="29.3"/>
                    <measurement group_id="B2" value="49.7" spread="25.7"/>
                    <measurement group_id="B3" value="74.6" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injection Volume</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="0.9"/>
                    <measurement group_id="B2" value="3.3" spread="0.8"/>
                    <measurement group_id="B3" value="2.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Composite Success</title>
        <description>Subject success based on a composite of minimum 30% decrease in low back pain, 30% improvement in function, maintenance of neurological status, no secondary interventions, and no serious adverse events.</description>
        <time_frame>26 weeks</time_frame>
        <population>All subjects adjudicated as a success or failure. Missed 26-week visit counted as failure (7 BIOSTAT BIOLOGX; 2 Saline). Unblinded subjects counted as failures (2 BIOSTAT BIOLOGX).</population>
        <group_list>
          <group group_id="O1">
            <title>BIOSTAT BIOLOGX</title>
            <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
BIOSTAT BIOLOGX: One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
Saline: One injection of up to 4 mL of saline using the Biostat Delivery Device</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Composite Success</title>
          <description>Subject success based on a composite of minimum 30% decrease in low back pain, 30% improvement in function, maintenance of neurological status, no secondary interventions, and no serious adverse events.</description>
          <population>All subjects adjudicated as a success or failure. Missed 26-week visit counted as failure (7 BIOSTAT BIOLOGX; 2 Saline). Unblinded subjects counted as failures (2 BIOSTAT BIOLOGX).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null: No differenc between the percent success of Saline and BIOSTAT BIOLOGX</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale for Low Back Pain</title>
        <description>Percent of subjects achieving a minimum 30% decrease in pain from baseline.
The visual analog scale is a horizontal 100 mm line anchored on the left with the words “No Pain” and on the right with the words “Worst Possible Pain”. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the subject to indicate the subject’s level of low back pain experienced over the last week.</description>
        <time_frame>26-weeks</time_frame>
        <population>All subjects assigned success or failure. Missed 26-week visit counted as failure (7 BIOSTAT BIOLOGX; 2 Saline). Unblinded subjects counted as failures (2 BIOSTAT BIOLOGX).</population>
        <group_list>
          <group group_id="O1">
            <title>BIOSTAT BIOLOGX</title>
            <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale for Low Back Pain</title>
          <description>Percent of subjects achieving a minimum 30% decrease in pain from baseline.
The visual analog scale is a horizontal 100 mm line anchored on the left with the words “No Pain” and on the right with the words “Worst Possible Pain”. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the subject to indicate the subject’s level of low back pain experienced over the last week.</description>
          <population>All subjects assigned success or failure. Missed 26-week visit counted as failure (7 BIOSTAT BIOLOGX; 2 Saline). Unblinded subjects counted as failures (2 BIOSTAT BIOLOGX).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Roland-Morris Disability Questionnaire Score</title>
        <description>Percent of subjects achieving a minimum 30% decrease in Roland-Morris Disability Questionnaire score
The Roland-Morris Disability Questionnaire is a widely studied and frequently used instrument for the assessment of function and disability related to low back pain. The questionnaire consists of 24 statements related to how a subject’s back condition affects various activities of daily living. Subjects marked whether the statement either applied to them or did not apply at the time they responded to the statements. The score is the total number of questions with which the subject agreed. A higher score indicates less function and greater disability.</description>
        <time_frame>26-weeks</time_frame>
        <population>All subjects assigned as success or failure. Missed 26-week visit counted as failure (7 BIOSTAT BIOLOGX; 2 Saline). Unblinded subjects counted as failures (2 BIOSTAT BIOLOGX).</population>
        <group_list>
          <group group_id="O1">
            <title>BIOSTAT BIOLOGX</title>
            <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
          </group>
        </group_list>
        <measure>
          <title>Roland-Morris Disability Questionnaire Score</title>
          <description>Percent of subjects achieving a minimum 30% decrease in Roland-Morris Disability Questionnaire score
The Roland-Morris Disability Questionnaire is a widely studied and frequently used instrument for the assessment of function and disability related to low back pain. The questionnaire consists of 24 statements related to how a subject’s back condition affects various activities of daily living. Subjects marked whether the statement either applied to them or did not apply at the time they responded to the statements. The score is the total number of questions with which the subject agreed. A higher score indicates less function and greater disability.</description>
          <population>All subjects assigned as success or failure. Missed 26-week visit counted as failure (7 BIOSTAT BIOLOGX; 2 Saline). Unblinded subjects counted as failures (2 BIOSTAT BIOLOGX).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>78-weeks postprocedure or until study termination for those subjects not reaching the 78-week follow-up examination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BIOSTAT BIOLOGX</title>
          <description>One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc using the Biostat Delivery Device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Conversion Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Eating Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Substance Abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure restrictions:
Sponsor can review results communication prior to public release and can embargo communications regarding trial results for up to 30 days from the time submitted for review.
If the communication contains patentable invention information, disclosure may be delayed up to 6 months for patent application filing.
If the communication contains confidential information, Sponsor will notify the PI to remove the confidential information prior to release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Doerzbacher</name_or_title>
      <organization>formerly Spinal Restoration, Inc</organization>
      <email>jdoerzbacher@renascentmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

